Botulism medical therapy
|
Botulism Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Botulism medical therapy On the Web |
|
American Roentgen Ray Society Images of Botulism medical therapy |
|
Risk calculators and risk factors for Botulism medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Michael Maddaleni, B.S., Tarek Nafee, M.D. [2], Keanu Ngo[3]
Overview
The two pillars of botulism management are early passive immunization with botulinum antitoxin and meticulous supportive/critical care, particularly respiratory support. Clostridium botulinum is a bacterium; its neurotoxin (BoNT) produces the flaccid paralysis of botulism. Antitoxin arrests progression but does not reverse established paralysis, so it must be given as early as possible—ideally within 24 hours and no later than 48 hours after symptom onset—and should never be delayed for laboratory confirmation. Almost all patients survive if they receive supportive care, including mechanical ventilation when required.[1][2][3]
General principles
- Contact the state/local health department (and, through them, the CDC) immediately when botulism is suspected, to arrange antitoxin and confirmatory testing.[2]
- Treat on clinical suspicion. Timely antitoxin minimizes subsequent nerve damage; administration beyond 48 hours is associated with longer ICU and hospital stays and decreased survival.[1][2] Early treatment (≤2 days of onset) shortens hospital stay, ICU stay, and duration of mechanical ventilation.[4][5]
- Antitoxin does not reverse established paralysis; recovery requires regeneration of nerve terminals over weeks to months.[2][3]
Antitoxin therapy
Non-infant botulism (equine heptavalent antitoxin, BAT/HBAT)
Equine-derived heptavalent botulinum antitoxin (BAT/HBAT) neutralizes serotypes A–G and is the product for adults, children ≥1 year, and infants with foodborne, wound, or non–A/B (e.g., type F) disease. It is obtained through the CDC via state/local health departments.[2][4]
- Dose: a single vial per patient. Exposure-response modeling predicts a survival probability >95.9% for all serotypes after one vial.[6]
- Adult infusion: starting rate 0.5 mL/min for the first 30 minutes; if tolerated, double the rate every 30 minutes to a maximum of 2 mL/min.[5]
- Pediatric dose (percentage of the adult vial): children 1–17 years, 20–100% of the adult dose; children <1 year, 10% of the adult dose regardless of body weight. Infusion: start 0.01 mL/kg/min, increase by 0.01 mL/kg/min every 30 minutes if tolerated, to a maximum of 0.03 mL/kg/min.[5][4]
- Safety: graded infusion with epinephrine available; anaphylaxis occurs in approximately 1.4% of patients, and serious antitoxin-related adverse events occurred in about 4% of a treatment registry.[2][5]
Infant botulism (human BIG-IV, BabyBIG)
For infant botulism caused by toxin type A or B in patients <1 year, use human-derived Botulism Immune Globulin Intravenous (BIG-IV; BabyBIG), obtained through the California Infant Botulism Treatment and Prevention Program.[7]
- Dose: 1.0 mL/kg (50 mg/kg) as a single IV infusion, given as soon as the clinical diagnosis is made.
- Infusion: begin at 0.5 mL/kg/h (25 mg/kg/h); if no reaction after 15 minutes, increase to a maximum of 1.0 mL/kg/h (50 mg/kg/h). Do not exceed this rate.
- Precaution: use with caution in pre-existing or increased risk of renal insufficiency (diabetes, volume depletion, sepsis, nephrotoxic drugs); discontinue and give epinephrine for anaphylaxis or significant hypotension.[7]
- Infants with foodborne, wound, or non–A/B disease receive HBAT, not BabyBIG.[5]
Supportive and critical care
Supportive care is the cornerstone of management.[1]
- Monitor closely for respiratory failure; the decision to intubate should rest on clinical judgment, because hypoxemia and hypercarbia are late findings and bulbar/facial weakness can mask signs of distress. Tracheal intubation and mechanical ventilation are required in 50–80% of hospitalized infants, usually within 24 hours of presentation.[8]
- Severe disease may require weeks to months of mechanical ventilation, with fluid and nutritional support and treatment of complications.[3][2]
Antimicrobial therapy
Antibiotics have a restricted role and are not indicated for foodborne or infant botulism; the role in adult intestinal colonization botulism is not established.[9]
- Avoid aminoglycosides and clindamycin, which potentiate neuromuscular blockade and may precipitate respiratory arrest.[9]
- In infant botulism, antibiotics may lyse intraluminal C. botulinum and release additional toxin; give only after BIG-IV and reserve for secondary infections (e.g., pneumonia, urinary tract infection).[9]
- Wound botulism: wound exploration and debridement (ideally after antitoxin), with anaerobic cultures obtained intraoperatively. Penicillin G is the drug of choice (children: 250,000–400,000 U/kg/day for 10–14 days; adult clostridial botulism adjunctive dosing ~20 million units/day per the FDA label). Metronidazole has been suggested as an alternative, but its effectiveness in botulism has not been demonstrated.[9][10]
Investigational and adjunctive therapies
Guanidine hydrochloride, 3,4-diaminopyridine (a presynaptic potassium-channel blocker), and plasma exchange have been proposed to enhance acetylcholine release or remove circulating toxin, but none is established as standard therapy.[11]
References
- ↑ 1.0 1.1 1.2 Kuehn BM (2021). "Botulism Guidelines Aim to Help Prepare Clinicians for Outbreaks". JAMA. 325 (24): 2428. doi:10.1001/jama.2021.8969.
- ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 Gayed SMA; Motley MP; Carlson JM; Lupu KS; Mavrogiorgos N (2026). "The Eyes Have It". The New England Journal of Medicine. 394 (10): 1011–1017. doi:10.1056/NEJMcps2508044.
- ↑ 3.0 3.1 3.2 Arnon SS; Schechter R; Inglesby TV; et al. (2001). "Botulinum Toxin as a Biological Weapon: Medical and Public Health Management". JAMA. 285 (8): 1059–1070. doi:10.1001/jama.285.8.1059.
- ↑ 4.0 4.1 4.2 Yu PA; Lin NH; Mahon BE; et al. (2017). "Safety and Improved Clinical Outcomes in Patients Treated With New Equine-Derived Heptavalent Botulinum Antitoxin". Clinical Infectious Diseases. PMID 29293928.
- ↑ 5.0 5.1 5.2 5.3 5.4 Richardson JS; Parrera GS; Astacio H; et al. (2020). "Safety and Clinical Outcomes of an Equine-Derived Heptavalent Botulinum Antitoxin Treatment for Confirmed or Suspected Botulism in the United States". Clinical Infectious Diseases. PMID 31209461.
- ↑ Beliveau M; Anderson D; Barker D; et al. (2022). "Exposure-Response Modeling and Simulation to Support Human Dosing of Botulism Antitoxin Heptavalent Product". Clinical Pharmacology and Therapeutics. PMID 35467014 Check
|pmid=value (help). - ↑ 7.0 7.1 Food and Drug Administration (2024). "BabyBIG (Botulism Immune Globulin Intravenous [Human]) prescribing information". Missing or empty
|url=(help) - ↑ Berkwitt A; El Saleeby CM; Murphy SA (2024). "Case 3-2024: An 8-Week-Old Male Infant with Inconsolable Crying and Weakness". The New England Journal of Medicine.
- ↑ 9.0 9.1 9.2 9.3 Carrillo-Marquez MA (2016). "Botulism". Pediatrics in Review. 37 (5): 183–192. doi:10.1542/pir.2015-0018.
- ↑ Food and Drug Administration (2023). "Penicillin G (sodium/potassium) for injection prescribing information". Missing or empty
|url=(help) - ↑ Chalk CH; Benstead TJ; Pound JD; Keezer MR (2019). "Medical Treatment for Botulism". Cochrane Database of Systematic Reviews. 4: CD008123. doi:10.1002/14651858.CD008123.pub4.